Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab for prevention of generalized pustular psoriasis flares
CTR20200917Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of spesolimab in generalized pustular psoriasis (GPP), sponsored by Boehringer Ingelheim. Started Jun 2020; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on CTR20200917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200917.